Celebrated, then disparaged: mRNA’s promise is tarnished under Trump

The future of mRNA technology is facing uncertainty as the Trump administration's HHS, led by Robert F. Kennedy Jr., takes actions that undermine confidence in mRNA vaccines, including removing vaccine experts and halting funding for Moderna's bird flu vaccine, despite the technology's proven efficacy in COVID-19 vaccines and potential in treating other diseases like cancer and cystic fibrosis; these actions have led to concerns within the scientific community about the future of mRNA research and its potential impact on public health, as well as a decline in Moderna's stock value.

Analysis

The landscape for mRNA technology faces significant headwinds driven by policy shifts within the new administration's Department of Health and Human Services (HHS), led by Robert F. Kennedy Jr. Key actions include the ousting of an influential vaccine advisory group and the appointment of members with records of disparaging mRNA vaccines, alongside direct criticism of the technology's safety despite its proven track record in combating the COVID-19 pandemic. This has manifested in tangible impacts, such as the termination of a $766 million HHS award to Moderna (MRNA) for developing an mRNA-based bird flu vaccine, a decision viewed by career staff as politically motivated. While the administration shows some inconsistency, maintaining funding for Arcturus Therapeutics' (ARCT) bird flu program (which received FDA fast-track status), the overarching sentiment from HHS has been critical, citing a need for more long-term safety data. Moderna, whose portfolio is entirely mRNA-based, has seen its stock value halve since the November election. The scientific community expresses alarm, with Nobel laureate Drew Weissman noting the loss of a federal grant for a universal coronavirus vaccine and fearing a generational setback for U.S. leadership in RNA science. State-level legislative efforts seeking to criminalize or restrict mRNA vaccines further compound these concerns, potentially impacting public perception and future development even for non-vaccine applications like cancer therapies, as highlighted by Moderna's promising melanoma vaccine trial with Merck (MRK) and research into cystic fibrosis treatments with Vertex (VRTX). The negative rhetoric also affects ancillary companies like Maravai LifeSciences (MRVI), which provides tools for mRNA therapy development. Despite mRNA vaccines, such as those from Moderna and Pfizer/BioNTech (PFE, BNTX), saving an estimated 20 million lives in their first year and demonstrating safety and efficacy in large clinical trials, the current environment fosters widespread skepticism and uncertainty for the technology's future trajectory and investment. The overall sentiment derived from the article is strongly negative, with a moderate market impact score, reflecting the political and regulatory pressures on this innovative healthcare sector.

Key Decisions for Investors

• Investors should closely monitor statements and policy actions from HHS and the FDA regarding mRNA technology, as these are primary drivers of volatility for exposed companies, particularly Moderna (MRNA).
• Consider the bifurcation in the market: while pure-play mRNA companies like Moderna face significant political headwinds and stock pressure, companies with diversified portfolios or specific, still-supported mRNA projects like Arcturus Therapeutics (ARCT) may present different risk-reward profiles.
• Evaluate the long-term disruptive potential of mRNA in treating a wide range of diseases, including cancer and rare genetic disorders, against the current near-term political and public perception risks, which could create discounted entry points for those with a higher risk tolerance.
• For companies like Maravai LifeSciences (MRVI), assess the potential for reduced demand from mRNA developers if research funding and development initiatives broadly contract due to the negative sentiment.
• Diversified pharmaceutical companies involved in mRNA partnerships, such as Pfizer (PFE), BioNTech (BNTX), Merck (MRK), and Vertex (VRTX), may experience secondary impacts, but their broader portfolios could mitigate direct exposure compared to dedicated mRNA firms.